Last October, a little deaf boy regained his hearing after 11 years spent in complete silence.
Aissam Dam is the first American patient to have his hearing treated with gene therapy.
A few days after this treatment, he heard the sound of cars on the streets of Philadelphia for the first time.
Two months later, his hearing was almost normal.
Spectacular results relayed on the cover of the
New York Times
.
The biotech behind this feat is an American company, Akouos, bought in October 2022 by the American laboratory Elli Lilly for nearly $500 million.
But France also has its nugget, which has been working for several years in this field, and has just obtained authorization to start a clinical trial in Europe as part of a strategic partnership with the Pasteur Institute.
Unlike Akouos, which has only obtained authorization to treat children aged over 7, Sensorion will treat in…
This article is reserved for subscribers.
You have 72% left to discover.
Flash sale
-70% on digital subscription
I ENJOY IT
Already subscribed?
Log in